Heparanase

Heparanase
250px Crystal structure of human heparanase
Identifiers
EC number	3.2.1.166
CAS number	137675-95-1
Databases
IntEnz	IntEnz view
BRENDA	BRENDA entry
ExPASy	NiceZyme view
KEGG	KEGG entry
MetaCyc	metabolic pathway
PRIAM	profile
PDB structures	RCSB PDB PDBe PDBsum
Gene Ontology	AmiGO / QuickGO
Search PMC articles PubMed articles NCBI proteins

Heparanase is an endo-β-D-glucuronidase enzyme that specifically cleaves heparan sulfate (HS) side chains of heparan sulfate proteoglycans (HSPGs) in the extracellular matrix (ECM) and on cell surfaces. This enzymatic activity is crucial in the remodeling of the ECM and is implicated in various physiological and pathological processes, including tumor metastasis, angiogenesis, and inflammation.

Structure

Heparanase is synthesized as a latent 65 kDa precursor that undergoes proteolytic processing to yield an active heterodimer composed of an 8 kDa and a 50 kDa subunit. The active site of heparanase is located within the 50 kDa subunit, which contains the catalytic residues necessary for its enzymatic function.

Function

Heparanase degrades heparan sulfate chains by cleaving the β(1→4) glycosidic bond between glucuronic acid and glucosamine residues. This activity results in the release of bioactive molecules sequestered within the ECM, such as growth factors and cytokines, thereby modulating cell behavior and tissue dynamics.

Role in Cancer

Heparanase is overexpressed in many types of cancer, where it facilitates tumor cell invasion and metastasis by degrading the ECM and basement membranes. This degradation allows cancer cells to penetrate tissue barriers and spread to distant sites. Additionally, heparanase activity promotes angiogenesis by releasing angiogenic factors like vascular endothelial growth factor (VEGF).

Role in Inflammation

In the context of inflammation, heparanase contributes to leukocyte extravasation by remodeling the ECM and facilitating the migration of immune cells to sites of inflammation. It also modulates the activity of inflammatory mediators, influencing the inflammatory response.

Clinical Implications

Given its role in cancer and inflammation, heparanase is a target for therapeutic intervention. Inhibitors of heparanase are being developed to prevent tumor metastasis and reduce inflammation. These inhibitors aim to block the enzymatic activity of heparanase, thereby preserving the integrity of the ECM and inhibiting the release of pro-tumorigenic and pro-inflammatory factors.

Research Directions

Current research is focused on understanding the regulation of heparanase expression and activity, as well as its interactions with other molecules in the ECM. Studies are also exploring the potential of heparanase inhibitors in clinical settings, particularly in cancer therapy.

Also see

• Heparan sulfate
• Extracellular matrix
• Tumor metastasis
• Angiogenesis
• Inflammation